Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2006; 12(41): 6715-6721
Published online Nov 7, 2006. doi: 10.3748/wjg.v12.i41.6715
Table 2 Response to treatment at the end of therapy n (%)
T-α1 (n = 29)IFN-α (n = 33)HC (after 6 mo of follow-up) (n = 30)
ALT normalization11 (37.9)16 (48.5)b5 (16.7)
Negative HBV DNA16 (55.2)c22 (66.7)c2 (6.7)
ALT normal/nagative HBeAg & HBVDNA9 (31.0)b15 (45.5)c1 (3.3)